X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (795) 795
Publication (45) 45
Book Chapter (9) 9
Newsletter (9) 9
Book Review (6) 6
Conference Proceeding (6) 6
Reference (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lanthanum (382) 382
index medicus (342) 342
humans (312) 312
lanthanum carbonate (202) 202
male (199) 199
urology & nephrology (173) 173
hyperphosphatemia (144) 144
female (142) 142
lanthanum - therapeutic use (139) 139
animals (134) 134
middle aged (120) 120
hyperphosphatemia - drug therapy (109) 109
aged (106) 106
lanthanum - adverse effects (103) 103
hemodialysis-patients (102) 102
calcium (101) 101
phosphates (101) 101
sevelamer (101) 101
analysis (93) 93
environmental sciences (93) 93
chelating agents - therapeutic use (89) 89
phosphate binder (88) 88
phosphates - blood (83) 83
hemodialysis (82) 82
phosphorus (81) 81
renal dialysis (80) 80
phosphate binders (77) 77
treatment outcome (77) 77
kidney failure, chronic - therapy (75) 75
chronic kidney-disease (73) 73
lanthanum - pharmacology (73) 73
hyperphosphatemia - etiology (72) 72
rats (70) 70
chronic kidney disease (68) 68
lanthan (68) 68
chronic-renal-failure (64) 64
kidney failure, chronic - complications (64) 64
rare-earth-elements (64) 64
mortality (63) 63
adult (62) 62
dialysis (61) 61
sevelamer hydrochloride (61) 61
chronic kidney failure (60) 60
phosphate (60) 60
calcium-carbonate (59) 59
lanthanum - administration & dosage (59) 59
cerium (58) 58
calcification (57) 57
dialysis patients (57) 57
nephrology (57) 57
rare earth metals (57) 57
polyamines - therapeutic use (56) 56
chemistry, physical (54) 54
coronary-artery calcification (53) 53
pharmacology & pharmacy (53) 53
serum phosphorus (52) 52
carbonates (51) 51
dose-response relationship, drug (51) 51
renal dialysis - adverse effects (51) 51
toxicology (51) 51
efficacy (48) 48
aluminum (47) 47
calcium - blood (46) 46
calcium carbonate (46) 46
chelating agents - adverse effects (46) 46
mineral metabolism (46) 46
toxicity (46) 46
materials science, multidisciplinary (45) 45
phosphates - metabolism (45) 45
phosphorus - blood (45) 45
vascular calcification (45) 45
kidney diseases (44) 44
rare earth elements (44) 44
growth (43) 43
stage renal-disease (43) 43
medicine & public health (41) 41
parathyroid hormone - blood (41) 41
time factors (41) 41
adsorption (39) 39
safety (39) 39
lanthanum - pharmacokinetics (38) 38
disease (35) 35
biochemistry & molecular biology (34) 34
lanthanum - metabolism (34) 34
hyperphosphatemia - blood (33) 33
lanthanum - toxicity (33) 33
life sciences (33) 33
renal insufficiency, chronic - complications (33) 33
research (33) 33
kidney failure, chronic - drug therapy (32) 32
mortality risk (32) 32
nanoparticles (32) 32
parathyroid-hormone (32) 32
calcium carbonate - therapeutic use (31) 31
engineering, environmental (31) 31
kidney failure, chronic - blood (31) 31
renal insufficiency, chronic - drug therapy (31) 31
administration, oral (30) 30
lanthanum - chemistry (30) 30
mice (30) 30
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (784) 784
Japanese (12) 12
Spanish (8) 8
French (4) 4
Chinese (2) 2
German (2) 2
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 08/2018, Volume 2018, Issue 8, p. CD006023
Background Phosphate binders are used to reduce positive phosphate balance and to lower serum phosphate levels for people with chronic kidney disease (CKD)... 
Bone Diseases | Metabolic [drug therapy | prevention & control]; Calcium [blood | JAPANESE HEMODIALYSIS-PATIENTS | Phosphorus [blood] | Calcium Compounds [adverse effects; therapeutic use] | RANDOMIZED CLINICAL-TRIAL | PERITONEAL-DIALYSIS PATIENTS | Parathyroid Hormone [blood] | Randomized Controlled Trials as Topic | Hypercalcemia [chemically induced] | MEDICINE, GENERAL & INTERNAL | PARATHYROID-HORMONE LEVELS | CORONARY-ARTERY CALCIFICATION | Polyamines [adverse effects; therapeutic use] | Sevelamer Humans | GROWTH-FACTOR 23 | ORAL FERRIC CITRATE | PLACEBO-CONTROLLED TRIAL | Kidney Diseases [blood; complications] | Chronic Disease | Chelating Agents [adverse effects; therapeutic use] | CHRONIC-RENAL-FAILURE | CALCIUM ACETATE/MAGNESIUM CARBONATE | Chronic Kidney Disease-Mineral and Bone Disorder - blood | Polyamines - adverse effects | Humans | Middle Aged | Polyamines - therapeutic use | Parathyroid Hormone - blood | Cause of Death | Sevelamer - therapeutic use | Calcium - blood | Calcium Compounds - adverse effects | Calcium Compounds - therapeutic use | Chronic Kidney Disease-Mineral and Bone Disorder - prevention & control | Adult | Iron Compounds - therapeutic use | Chelating Agents - therapeutic use | Iron Compounds - adverse effects | Lanthanum - adverse effects | Lanthanum - therapeutic use | Chelating Agents - adverse effects | Renal Dialysis - statistics & numerical data | Hypercalcemia - chemically induced | Chronic Kidney Disease-Mineral and Bone Disorder - drug therapy | Disease Progression | Phosphorus - blood | Aged
Journal Article
Kidney International, ISSN 0085-2538, 06/2003, Volume 63, Issue S85, pp. S73 - S78
Journal Article
British Journal of Dermatology, ISSN 0007-0963, 02/2008, Volume 158, Issue 2, pp. 273 - 280
Journal Article